Therapeutic use of propranolol for intermittent explosive disorder (Q39758966)

14 September 2017

1 reference

title

Therapeutic use of propranolol for intermittent explosive disorder (English)

1 reference

14 September 2017

S C Jenkins

1

1 reference

PubMed ID

3546964

14 September 2017

T Maruta

series ordinal

2

1 reference

PubMed ID

3546964

14 September 2017

language of work or name

English

0 references

publication date

1 March 1987

1 reference

14 September 2017

1 reference

14 September 2017

62

1 reference

14 September 2017

3

1 reference

14 September 2017

204-214

1 reference

Propranolol for the control of belligerent behavior following acute brain damage

14 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962444-6

Propranolol in the treatment of rage and violent behavior in patients with chronic brain syndromes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962444-6

Use of propranolol for provoked and unprovoked episodes of rage.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962444-6

Propranolol in the treatment of rage and violent behavior associated with Korsakoff's psychosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962444-6

The effect of propranolol on uncontrolled rage outbursts in children and adolescents with organic brain dysfunction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962444-6

Neurological findings in adult minimal brain dysfunction and the dyscontrol syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962444-6

Episodic dyscontrol: a study of 130 violent patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962444-6

An empirical analysis of specific syndromes of violent behavior.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962444-6

Lithium in aggressive behavior

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962444-6

The long-term use of lithium in aggressive prisoners.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962444-6

Carbamazepine in the treatment of aggressive behavior in schizophrenic patients: a case report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962444-6

Carbamazepine for uncontrolled rage outbursts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962444-6

Episodic dyscontrol disorder and paroxysmal EEG abnormalities: successful treatment with carbamazepine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962444-6

ANTICONVULSANTS IN THE TREATMENT OF AGGRESSION

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962444-6

Preliminary data on ethosuximide and the episodic dyscontrol syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962444-6

Methylphenidate in the treatment of aggression in two patients with antisocial personality disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962444-6

Brain research and violent behavior. A summary and evaluation of the status of biomedical research on brain and aggressive violent behavior. Neuroanatomical and neurophysiologic studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962444-6

Use of propranolol in the treatment of postencephalitic psychosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962444-6

Propranolol in organic agitation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962444-6

Metoprolol for intermittent explosive disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962444-6

The Overt Aggression Scale for the objective rating of verbal and physical aggression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962444-6

Propranolol dosage, plasma concentration, and beta blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962444-6

Some clinical and metabolic aspects of propranolol in chronic schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962444-6

The effect of propranolol on CSF amine metabolites in psychiatric patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962444-6

Propranolol in schizophrenia. II. Clinical and biochemical aspects of combining propranolol with chlorpromazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962444-6

Adverse effects of combined propranolol and chlorpromazine therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962444-6

Hypotension and cardiopulmonary arrest associated with concurrent haloperidol and propranolol therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962444-6

Psychiatric Uses of Antiadrenergic and Adrenergic Blocking Drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962444-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Lithium in the treatment of aggression

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962444-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Propranolol treatment of assaultive patients with organic brain disease. A double-blind crossover, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962444-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0025-6196(12)62444-6

1 reference

14 September 2017

1 reference

PubMed ID

3546964